Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

PHASE3TerminatedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

November 5, 2022

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions
COVID-19
Interventions
DRUG

Obeldesivir

Tablets administered orally without regard to food.

DRUG

Obeldesivir Placebo

Placebo tablets administered orally without regard to food.

Trial Locations (81)

100

National Taiwan University Hospital, Taipei

320

Tao-Yuan General Hospital, Taoyuan

813

Kaohsiung Veterans General Hospital, Zuo Ying Qu

970

Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City

1431

Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia

1510

Medical Center Hera EOOD, Sofia

1618

Diagnostic Consultative Center XX - Sofia EOOD, Sofia

1619

Clinresco Centres (Pty) Ltd, City of Johannesburg

1938

FCRN Clinical Trial Centre (Pty) Ltd, Vereeniging

2000

Multiprofile Hospital for Active Treatment - Samokov EOOD, Department of Internal Diseases, Samokov

2013

Perinatal HIV Research Unit (PHRU), Johannesburg

2600

Medical Center Asklepii OOD, Dupnitsa

2700

Multiprofile Hospital for Active Treatment Puls AD, Department of Internal Diseases, Blagoevgrad

3000

Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa EOOD, Department of Pneumology, Vratsa

3010

Hospital General Universitario Dr. Balmis, Alicante

3320

Medical Center Zdrave-1 OOD, Kozloduy

3400

Medical Center Hera EOOD, Montana, Montana

Multiprofile Hospital for Active Treatment Dr. Stamen Iliev AD, Department of Pneumology Phthisiatrics, Montana

3600

Diagnostic Consultative Center 1 - Lon EOOD, Lom

4000

Diagnostic Consultative Center Sveti Georgi EOOD, Plovdiv

4001

Synapta Clinical Research Centre, Durban

4004

MHAT Sveta Karidad EAD, First Department of Anesthesiology and Intensive Care, Plovdiv

Multiprofile Hospital for Active Treatment Sveti Panteleymon EOOD, First Department of Internal Diseases, Plovdiv

4031

Debreceni Egyetem Klinikai Kozpont, Debrecen

5400

Medical Center Unimed EOOD, Sevlievo

5800

Medical Center Medconsult Pleven OOD, Pleven

6300

Specialìzed Hosp¡tal for Active Trealment of Pneumophthisiatric Diseases Haskovo EOOD, Department of pneumology and phthisiatry, Haskovo

7002

Medical Center Prolet EOOD, Rousse

8007

CAP La Mina, Barcelona

8023

Hospital HM Nou Delfos, Barcelona

13030

Panamerican Clinical Research Mexico S.A. de C.V., Col. El Salitre Juriquilla

20127

Unita Operativa Di Malattie Infettive Ospedale San Raffaele S.r.l., Milan

28031

Hospital Universitario Infanta Leonor, Madrid

28040

Hospital Clinico San Carlos, Madrid

28222

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda

30003

Hospital General Universitario Reina Sofia, Murcia

32540

Hospital Universitario Virgen de Las Nieves., A Gudiña

34090

CHU de Montpellier-Hopital La Colombiere, Montpellier

35015

ChungNam National University Hospital, Daejeon

40447

China Medical University Hospital, Taichung

41730

Hospital Universitario Virgen del Rocio, Las Cabezas de San Juan

44670

PanAmerican Clinical Research Mexico S.A de C.V., Guadalajara

46016

Hospital Universitaro y Politecnico La Fe, Valencia

50414

Ginemedica OVO 21, Wroclaw

61030

Acibadem University School of Medicine Atakent Hospital, Trabzon

61748

Chonnam National University Bitgoeul Hospital, Gwangju

68000

Oaxaca Site Management Organization S.C., Oaxaca City

75651

Hopital Pitie Salpetriere, Paris

80020

Neurociencias Estudios Clinicos S.C., Culiacan Sinaloa

91900

FAICIC S. de R.L. de C.V., Veracruz

97000

EME RED Hospitalaria, Mérida

97070

Kohler & Milstein Research S.A de C.V., Mérida

235200

County Hospital Caracal, Caracal

308433

National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore

550253

Sibiu Emergency Clinical County Hospital, Sibiu

30130-100

Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte - MG

70200-730

L2iP Instituto de Pesquisas Clínicas, Brasília - DF

09530-905

Centro de Pesquisa Clinica da Universidade Municipal de São Caetano do Sul (USCS), São Caetano Do Sul - SP

L8M 1K7

Hamilton Medical Research Group, Hamilton

M9V 4B4

Dr. Anil K. Gupta Medicine Professional Corporation, Toronto

V6Z 2C9

Vancouver ID Research and Care Centre Society, Vancouver

286-0124

IUHW Narita Hospital, Chibaken

700-8558

Okayama University Hospital, Okayama

564-8567

Suita Municipal Hospital, Suita

06700

Clinstile, S.A. De C.V., Mexico City

95-100

ETG Lodz, Zgierz

96-100

ClinMedica Research, Skierniewice

1998-018

Hospital CUF Descobertas, Lisbon

4520-211

Centro Hospitalar de Entre Douro e Vouga - Hospital de Sao Sebaststiao, Santa Maria da Feira

4099-346

Hospital da Luz - Arrabida, Vila Nova de Gaia

021105

"Prof. Dr. Matei Bals National Institute for Infectious Diseases", Bucharest

0250

Madibeng Centre for Research, Brits

0001

Global Clinical Trials, Pretoria

0183

Jongaie Research, Pretoria West

0380

Limpopo Clinical Research Initiative, Thabazimbi

152-703

Korea University Guro Hospital, Seoul

08916

Hospital Universitari Germans Trias i Pujol, Badalona

07120

Hospital Universitario Son Espases, Palma de Mallorca

BT7 2EB

Ormeau Clinical Trials Limited, Belfast

NN17 2UR

Lakeside Healthcare, Corby

G20 0XA

CPS Research, Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05603143 - Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness | Biotech Hunter | Biotech Hunter